Filing Flows › Companies › Tandem Diabetes Care › Timeline
Tandem Diabetes Care stock timeline
A year of the price with every insider trade, planned sale, earnings report and material 8-K marked
252 sessions+26.8% to $16.91
Tandem Diabetes Care (TNDM) stock rose 27% over the last 252 sessions, to $16.91. On the way it reported 5 quarters, its insiders filed no open-market trades (10b5-1 plan sales aside) and 1 Form 144 notice of planned sales, and the company filed 4 material 8-Ks. Each is marked on the price and listed with what the stock did next.
Each mark, and what followed
| Date | Kind | What | Next session | 5 sessions | 21 sessions |
|---|---|---|---|---|---|
| Nov 5, 2026 | Earnings | Earnings: beat the EPS estimate by 58.4% | −5.7% (−1.2% vs SPY) | — | — |
| Oct 27, 2026 | Form 144 | Form 144: Christopher Twomey plans to sell $32K | +1.7% (+1.1% vs SPY) | −1.2% (+0.5% vs SPY) | — |
| Aug 6, 2026 | Earnings | Earnings: beat the EPS estimate by 2.7% | −4.2% (−4.0% vs SPY) | +17.9% (+17.6% vs SPY) | +4.2% (+3.8% vs SPY) |
| May 21, 2026 | 8-K | Directors and officers: departures, appointments, pay | −5.2% (−5.6% vs SPY) | +8.7% (+6.9% vs SPY) | −9.0% (−8.0% vs SPY) |
| May 15, 2026 | 8-K | Directors and officers: departures, appointments, pay | −9.9% (−8.7% vs SPY) | +10.8% (+11.5% vs SPY) | +16.9% (+16.0% vs SPY) |
| May 7, 2026 | Earnings | Earnings: beat the EPS estimate by 32.1% | +2.4% (+2.7% vs SPY) | −24.5% (−25.7% vs SPY) | +7.0% (+6.5% vs SPY) |
| Feb 27, 2026 | 8-K | Material definitive agreement | −0.3% (−0.3% vs SPY) | −18.0% (−16.0% vs SPY) | −25.6% (−17.7% vs SPY) |
| Feb 19, 2026 | Earnings | Earnings: beat the EPS estimate by 88.9% | −2.2% (−2.0% vs SPY) | +31.7% (+30.7% vs SPY) | +26.3% (+30.2% vs SPY) |
| Nov 12, 2025 | 8-K | Directors and officers: departures, appointments, pay | +3.0% (+3.0% vs SPY) | +6.6% (+10.0% vs SPY) | +18.0% (+17.1% vs SPY) |
| Nov 6, 2025 | Earnings | Earnings: beat the EPS estimate by 8.9% | −9.6% (−8.5% vs SPY) | +20.8% (+19.9% vs SPY) | +35.5% (+34.3% vs SPY) |
What this kind of 8-K usually did
| Item | 8-Ks | Next session, median | Up next session | 21 sessions, median | Typical size |
|---|---|---|---|---|---|
| 5.02 Directors and officers: departures, appointments, pay | 39,174 | −0.1% | 48% | +0.7% | ±1.4% |
| 1.01 Material definitive agreement | 23,525 | 0.0% | 51% | +1.0% | ±1.4% |
| 2.03 New debt or off-balance-sheet obligation | 13,268 | 0.0% | 50% | +1.2% | ±1.3% |
Across every company in the move-odds universe, measured from the close before the filing. Every 8-K item ranked →
Report card: every quarter against the estimate → Tandem Diabetes Care: every quarter → Live insider trades →
Prices are daily closes; filings and trades are as filed with the SEC (Form 4 within two business days of the trade, 8-K within four of the event). Moves after a mark are the stock's close-to-close change and the same for SPY; they describe the record, not what the next one will do. Not investment advice.